Published in J Clin Oncol on January 07, 2008
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med (2016) 5.18
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol (2010) 4.43
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat (2010) 3.35
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat (2012) 3.02
Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol (2009) 2.14
Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol (2011) 2.00
Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer (2009) 1.84
The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J (2012) 1.64
Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist (2013) 1.49
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol (2010) 1.44
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat (2009) 1.37
Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer (2013) 1.36
Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat (2013) 1.21
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst (2013) 1.19
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat (2009) 1.19
Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res (Phila) (2011) 1.19
Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol (2014) 1.16
Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer (2008) 1.16
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res (2010) 1.14
Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer (2013) 1.11
Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat (2012) 1.09
Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract (2012) 1.05
Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol (2013) 1.02
The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst (2014) 1.01
Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol (2015) 1.01
Oral antineoplastic agents: how do we care about adherence? Br J Clin Pharmacol (2015) 0.99
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev (2011) 0.98
Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer (2013) 0.96
Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. Breast Cancer Res Treat (2012) 0.95
Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst (2012) 0.95
Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer (2012) 0.95
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res (2008) 0.95
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. Br J Cancer (2013) 0.95
Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum (2014) 0.94
Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer (2011) 0.93
Patient adherence to aromatase inhibitor treatment in the adjuvant setting. Curr Oncol (2011) 0.91
Providers of follow-up care in a population-based sample of breast cancer survivors. Breast Cancer Res Treat (2014) 0.90
Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract (2011) 0.89
Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy. Cancer Nurs (2009) 0.89
Adherence to hormone therapy among women with breast cancer. BMC Cancer (2014) 0.89
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J Natl Cancer Inst (2015) 0.89
Pain in cancer survivors. J Clin Oncol (2014) 0.89
Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study. BMC Cancer (2013) 0.89
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol (2016) 0.88
Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study. Breast Cancer Res Treat (2012) 0.87
Moving research from bench to bedside to community: there is still more to do. J Clin Oncol (2008) 0.87
Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer (2008) 0.86
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol (2010) 0.86
Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res (2011) 0.86
Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice? Springerplus (2014) 0.86
The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast (2011) 0.86
Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg (2014) 0.84
Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. Cancer Prev Res (Phila) (2013) 0.84
Pharmacogenomics of endocrine therapy in breast cancer. J Hum Genet (2013) 0.84
Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women--an Asian population-based study. PLoS One (2014) 0.84
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women. Breast Cancer (Auckl) (2011) 0.83
CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol (2011) 0.83
Physicians' influence on breast cancer patient compliance. Ger Med Sci (2014) 0.82
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer (2013) 0.82
Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer (2014) 0.82
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd (2014) 0.82
Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause (2012) 0.82
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Breast Care (Basel) (2013) 0.81
The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy. Breast Cancer Res Treat (2015) 0.81
Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv (2014) 0.81
Engaging in health behaviors to lower risk for breast cancer recurrence. PLoS One (2013) 0.81
Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ (2013) 0.81
Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer (2013) 0.80
A Systematic Review of Adherence to Oral Antineoplastic Therapies. Oncologist (2016) 0.80
Quality of life among a population-based cohort of older patients with breast cancer. Breast (2014) 0.80
Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. Surg Today (2013) 0.79
Adjuvant therapy use among Appalachian breast cancer survivors. Medicine (Baltimore) (2015) 0.79
Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of a medical claims database. Wien Klin Wochenschr (2016) 0.79
The impact of overweight and obesity on breast cancer: data from Switzerland, so far a country little affected by the current global obesity epidemic. Gland Surg (2014) 0.79
Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. J Clin Oncol (2016) 0.79
Statins and Breast Cancer: Future Directions in Chemoprevention. Curr Breast Cancer Rep (2013) 0.78
Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D. Med Oncol (2016) 0.78
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations. Breast Cancer Res (2010) 0.78
Vitreo-retinal traction and anastrozole use. Breast Cancer Res Treat (2008) 0.78
Interventions to Alleviate Symptoms Related to Breast Cancer Treatments and Areas of Needed Research. J Cancer Sci Ther (2011) 0.78
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer (Dove Med Press) (2011) 0.78
Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. Breast J (2013) 0.78
Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer (2017) 0.77
Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer. Breast Cancer Res Treat (2015) 0.77
Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS One (2013) 0.77
Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast (2015) 0.77
Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study. Cancer Manag Res (2012) 0.77
Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat (2016) 0.77
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors. J Med Chem (2015) 0.77
The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms. Breast Cancer Res Treat (2011) 0.77
Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management. Support Care Cancer (2016) 0.76
Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect Ratio. Breast Care (Basel) (2009) 0.76
Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. J Clin Oncol (2016) 0.76
Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment in vivo. Oncoimmunology (2016) 0.76
Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93. Breast Cancer Res Treat (2013) 0.76
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 4.47
Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin (2009) 4.18
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA (2005) 3.43
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst (2008) 2.51
Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med (2009) 2.39
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med (2009) 2.04
GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Res (2011) 1.75
Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer (2007) 1.62
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol (2009) 1.61
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer (2002) 1.53
Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns (2005) 1.45
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol (2010) 1.44
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst (2010) 1.44
Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology (2007) 1.42
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2014) 1.38
ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol (2009) 1.38
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res (2011) 1.31
Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer (2007) 1.28
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol (2010) 1.27
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer (2013) 1.17
A review of contemporary data on surgically resected renal masses--benign or malignant? Urology (2013) 1.15
Newer monoclonal antibodies for hematological malignancies. Exp Hematol (2008) 1.13
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol (2011) 1.11
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys (2005) 1.05
Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol (2007) 1.05
Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clin Breast Cancer (2008) 1.03
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol (2003) 1.00
Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat (2005) 0.98
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat (2006) 0.95
Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations. J Cancer Educ (2007) 0.94
Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol (2008) 0.93
Cancer-related communication between female patients and male partners scale: A pilot study. Psychooncology (2006) 0.93
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol (2003) 0.92
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol (2010) 0.91
Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol (2008) 0.89
Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. J Sex Med (2012) 0.87
Implementing an interdisciplinary governance model in a comprehensive cancer center. Oncol Nurs Forum (2007) 0.86
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. J Cancer Surviv (2014) 0.85
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer (2006) 0.83
Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg (2008) 0.80
Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J (2011) 0.78
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2014) 0.78
Acute lymphoblastic leukemia with 4;11 translocation analyzed by a multi-modal strategy of conventional cytogenetics, FISH, morphology, flow cytometry and molecular genetics, and review of the literature. Exp Mol Pathol (2006) 0.77
Response. J Natl Cancer Inst (2016) 0.76
Male breast cancer networking and telephone support group: a model for supporting a unique population. Psychooncology (2014) 0.75
Q&A: Eric Winer on neoadjuvant clinical trials. Cancer Discov (2013) 0.75
Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer (2009) 0.75
Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. Cancer Chemother Pharmacol (2011) 0.75